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less than 60.3 months. By comparison, 
other authors reported the prevalence of 
CTS as 0 at 5 years  [2] when low-flux 
membranes and commercial (potential-
ly contaminated) dialysis fluid were 
used. Busch et al.  [1]  clearly overestimat-
ed the prevalence of CTS in their pa-
tients (median follow-up 31 months). 
 (2) Cross-sectional studies may establish 
associations, but not causality. Due to 
the nonrandomized design, confound-
ers may be unequally distributed among 
subgroups. Indeed, in the study by Busch 
et al.  [1] , patients treated with high-flux 
biocompatible dialyzer membranes had 
the highest dialysis duration, the lowest 
residual diuresis, and the highest circu-
lating   2 -microglobulin concentrations. 
Moreover, the use of high-flux mem-
branes was associated with a higher 
prevalence of CTS in the multivariate lo-
gistic regression analysis. These data are 
in contrast to other reports demonstrat-
ing lower   2 -microglobulin levels in 
high-flux HD compared to low-flux HD 
of similar HD vintage and a lower preva-
lence of CTS in these patients  [3, 4] . 
 Busch et al.  [1] report a high prevalence 
of carpal tunnel syndrome (CTS) in hemo-
dialysis (HD) patients in spite of the use of 
high-flux dialyzer membranes and ultra-
pure dialysis fluid. The article is of interest 
as dialysis-related amyloidosis (DRA) has 
been out of focus in the last decade.
 The interpretation of the data present-
ed is, however, hampered by the disadvan-
tages of the cross-sectional study design 
they chose.
 (1) One major pitfall of this descriptive 
study is the absence of a clear, specific 
and reproducible disease definition. 
The gold standard for the diagnosis
of DRA manifestations remains the im-
munohistological detection of amyloid. 
Clinical assessment of symptoms and 
signs may pave the way to the diagnosis, 
but do not prove the presence of amyloid 
deposits in CTS. The authors do not dif-
ferentiate between different causes (dia-
betes) of CTS nor grade the severity of 
destructive arthropathy, which may 
lead to overdiagnosis. The authors 
found a prevalence of CTS of 28.7% in 
HD patients with a dialysis vintage of 
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 (3) Cross-sectional studies ascertain ex-
posure and outcome at the same time. 
There is convincing evidence that the 
microbiological quality of the dialysis 
fluid is an important determinant of 
DRA  [5] . Unfortunately, the authors 
were not able to analyze the impact of 
the dialysis fluid purity on the preva-
lence of CTS. They had no information 
on this variable when their patients 
were dialysed before their investiga-
tions had started. 
 Our retrospective analysis of compara-
ble HD patient groups (1995–2010, a total 
of 147 patients, dialysis vintage at least 10 
years) undergoing predominantly (more 
than 75% of all sessions) either low-flux 
HD utilising commercial dialysis fluid or 
receiving ultrapure high-flux HD revealed 
a decrease in histologically proven CTS 
from 68 to 28% (unpublished data). This 
trend is in line with other studies  [6, 7] re-
porting a decreased prevalence of CTS over 
time. We agree with Busch et al.  [1] that 
DRA remains an unsolved problem of 
long-term maintenance HD. 
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 We thank Dr. Helmut Schiffl and col-
leagues for their comments on our study 
[1]. We absolutely agree that our study has 
several shortcomings being typical of 
many descriptive studies. The critique on 
the absence of a clear disease definition is 
correct. Due to the fact that our data were 
obtained from living subjects, no immu-
nohistological staining of amyloid was 
possible, as it was also clearly discussed in 
the study [1]. In the same context, an un-
pleasant and partly invasive nerve conduc-
tion testing of the median nerve was not 
done because it should have been per-
formed in all 385 participants, whether 
they had symptoms or not. Certainly, this 
test could have been applied only in pa-
tients having clinical signs because the 
combination of clinical symptoms and 
electrodiagnostic findings is the most val-
id way of diagnosing carpal tunnel syn-
drome (CTS) [2]. However, the outpatient 
nature of our study prohibited such de-
sign. It was not possible to examine all pa-
tients from the different dialysis centers by 
the same equipment and examiner which 
is a necessary prerequisite for correct diag-
nosis. Moreover, most patients declined 
additional diagnostic tests. It should be 
mentioned that the quoted reference re-
ported only on CTS in HD if patients re-
quired operation (0%  ! 8 years, 50% after 
14 years and 100% after 20 years) [3]. Rates 
reporting clinical findings are expected to 
be higher. Moreover, in our study, the rate 
of patients who were already treated by op-
eration was substantially higher (8.8%). 
Especially in these cases, the diagnosis of 
CTS should have been previously con-
firmed and thus indicate the higher rate of 
CTS in our HD population. Nevertheless, 
we agree with the assumption that several 
cases of CTS might have been caused by 
diseases other than dialysis-related amy-
loidosis (DRA). But unfortunately, the 
main clinical symptoms of CTS in DRA 
are identical to those of idiopathic CTS, or 
CTS accompanying other diseases [3]. 
Since age is a strong predictor of CTS and 
DRA [3, 4], it should be taken into account 
that our dialysis population was substan-
tially older (median 65.1 years) than in 
most other studies [3]. Moreover, several 
other known risk factors for CTS/ DRA 
could be confirmed in our trial [1]. The 
(paradoxical) findings concerning DRA 
and the use of high-flux dialyzers were ad-
equately discussed in our paper [1]. 
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 The cross-sectional and retrospective 
character of our study implies the non-
randomized design. This includes the ab-
sence of information concerning the use 
and the quality of dialysis fluid in the past 
which is an obvious limitation of our study 
[1]. Prospective studies strictly using dif-
ferent types of dialyzers in different pa-
tient groups are welcome and would help 
to solve some of the open questions. Due
to limitations regarding the length of our 
paper, these points could not be discussed 
in depth. The presented retrospective and 
currently unpublished observation in HD 
groups by Schiffl et al. showed a decrease 
in histologically proven CTS from 68% in 
the period 1990–2000 to 28% in the period 
2000–2010. Although details on these re-
sults are lacking, our clinical finding of 
31.7% CTS cases seems not quite different 
from their results [1]. 
 Besides discussion about rates, it 
should be noticed that our study was di-
rected to the potential causes of CTS in 
HD like malnutrition or increased serum 
concentrations of 2-microglobulin and 
advanced glycation end products.
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